| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD.V97.7.2084 |
| P698 | PubMed publication ID | 11264175 |
| P2093 | author name string | W Vainchenker | |
| F Eschwege | |||
| R M'Kacher | |||
| L Maggiorella | |||
| J Bourhis | |||
| E Deutsch | |||
| E Marangoni | |||
| S Vaganay | |||
| A G Turhan | |||
| A Dugray | |||
| B AbdulKarim | |||
| S D Rasy | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2084-2090 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | BCR-ABL down-regulates the DNA repair protein DNA-PKcs | |
| P478 | volume | 97 |
| Q89532437 | A CRISPR/Cas13-based approach demonstrates biological relevance of vlinc class of long non-coding RNAs in anticancer drug response |
| Q37857869 | Abnormalities of DNA repair mechanisms in common hematological malignancies |
| Q44746331 | An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation |
| Q35876010 | Apoptosis and genomic instability |
| Q58794449 | Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML) |
| Q37334605 | BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair |
| Q33727572 | BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP. |
| Q37743173 | BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia |
| Q39810024 | BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells. |
| Q28704493 | BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold |
| Q33796384 | BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells |
| Q42126174 | BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress |
| Q35022527 | BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability |
| Q39625105 | BCR/ABL stimulates WRN to promote survival and genomic instability. |
| Q40572217 | BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint |
| Q40728141 | Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. |
| Q33784347 | Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells |
| Q30875394 | Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation |
| Q46213854 | Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy |
| Q36058572 | Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining |
| Q34765301 | Chronic myelogenous leukemia: mechanisms underlying disease progression. |
| Q34631354 | Chronic myeloid leukaemia as a model of disease evolution in human cancer |
| Q38243861 | Current perspectives on the therapeutic aspects of chronic myelogenous leukemia |
| Q36324767 | DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia. |
| Q35123713 | DNA damage response and DNA repair - dog as a model? |
| Q34929930 | DNA double-strand break repair signalling: the case of RAD51 post-translational regulation. |
| Q46019051 | Detection of c-Abl kinase-promoted phosphorylation of Rad51 by specific antibodies reveals that Y54 phosphorylation is dependent on that of Y315. |
| Q40676163 | Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? |
| Q34281241 | Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis |
| Q36512142 | Fusion tyrosine kinases: a result and cause of genomic instability |
| Q36883073 | Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia |
| Q41964099 | Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells |
| Q53272675 | Genomic instability in chronic myeloid leukemia: targets for therapy? |
| Q37738460 | Genomic instability: The cause and effect of BCR/ABL tyrosine kinase |
| Q40790661 | Inhibition of Ku heterodimer DNA end binding activity during granulocytic differentiation of human promyelocytic cell lines |
| Q33736829 | Is homologous recombination really an error-free process? |
| Q37086196 | KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms |
| Q28266411 | Loss of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in gastric cancers |
| Q38452040 | Management of advanced-phase chronic myeloid leukemia |
| Q37360559 | Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. |
| Q38392667 | Natural course and biology of CML. |
| Q41817207 | Non-homologous DNA end joining in normal and cancer cells and its dependence on break structures. |
| Q37249487 | Normal Sequence and Activity but Reduced Levels of DNA-Pkcs in Human Lymphoblastic Cells Implicate Impaired Protein Stability with Radiosensitive Phenotype |
| Q34665985 | Oncogenic tyrosine kinases and the DNA-damage response |
| Q89187128 | PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions |
| Q36895345 | Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses |
| Q35022522 | Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins |
| Q38139571 | Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia |
| Q44500993 | Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia |
| Q35037746 | Protein kinases and their involvement in the cellular responses to genotoxic stress. |
| Q36997781 | Role of the double-strand break repair pathway in the maintenance of genomic stability. |
| Q37428655 | Signaling networks associated with BCR-ABL-dependent transformation |
| Q36150854 | Src kinases as targets for B cell acute lymphoblastic leukaemia therapy |
| Q37059746 | Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia |
| Q35459748 | Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors |
| Q33855938 | Taking a Bad Turn: Compromised DNA Damage Response in Leukemia |
| Q33688509 | The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia |
| Q52671466 | The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability. |
| Q37414369 | Tumor suppressor genes in myeloid differentiation and leukemogenesis |
| Q36695924 | Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. |
| Q54978631 | Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. |
| Q24619366 | Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks |
| Q24318820 | Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution |
| Q74622590 | [Mechanisms of radio-induced apoptosis] |
| Q39674140 | hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis |
Search more.